Submitted by amarin on Fri, 12/08/2017 - 04:48 Home ID Reference 8466 News title Amarin Corporation Announces First Patients Enrolled in Two Phase 3 Clinical Trials Assessing AMR101 for the Treatment of Cardiovascular Disease
